Targeted AST CirrusDx has recently launched antimicrobial susceptibility testing for gepotidacin, signaling an expansion in actionable resistance profiling. This creates opportunities to cross-sell expanded AST panels to customers seeking rapid, clinically actionable resistance data for uUTIs and related infections.

UTI Focused Strong emphasis on urinary tract infections and women’s health presents a clear entry point for hospitals and clinics prioritizing UTI diagnostics, antimicrobial stewardship, and rapid culture-informed treatment plans.

Integrated Diagnostics The blended molecular and culture-based approach with polyMIC offers a differentiator for institutions seeking comprehensive diagnostic insights that reduce empiric therapy, enabling value-based conversations about faster, more precise patient care.

Clinical Service Lag-free phone support and a dedicated clinical team can be highlighted to enterprise customers as a service differentiator, helping to reduce clinician time-to-answer and improve onboarding for new orders and complex testing panels.

Growing Revenue With reported annual revenue in the 10–25 million range and a CLIA-certified lab, CirrusDx presents a scalable partner for health systems seeking to augment diagnostic offerings with rapid, actionable test results and broader antimicrobial resistance insights.